IE83449B1 - Cell growth inhibitors - Google Patents
Cell growth inhibitorsInfo
- Publication number
- IE83449B1 IE83449B1 IE1991/3816A IE381691A IE83449B1 IE 83449 B1 IE83449 B1 IE 83449B1 IE 1991/3816 A IE1991/3816 A IE 1991/3816A IE 381691 A IE381691 A IE 381691A IE 83449 B1 IE83449 B1 IE 83449B1
- Authority
- IE
- Ireland
- Prior art keywords
- protein
- agglutinating
- gbp
- cell
- binding protein
- Prior art date
Links
- 239000003966 growth inhibitor Substances 0.000 title description 2
- 210000004027 cells Anatomy 0.000 claims description 133
- 102000004169 proteins and genes Human genes 0.000 claims description 120
- 108090000623 proteins and genes Proteins 0.000 claims description 119
- 230000002401 inhibitory effect Effects 0.000 claims description 49
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 230000012010 growth Effects 0.000 claims description 41
- 102000024070 binding proteins Human genes 0.000 claims description 38
- 108091007650 binding proteins Proteins 0.000 claims description 38
- 230000004523 agglutinating Effects 0.000 claims description 33
- 210000002950 fibroblast Anatomy 0.000 claims description 32
- 210000001161 Embryo, Mammalian Anatomy 0.000 claims description 28
- 150000001720 carbohydrates Chemical class 0.000 claims description 27
- 229920002676 Complementary DNA Polymers 0.000 claims description 25
- 210000001519 tissues Anatomy 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 13
- 230000010261 cell growth Effects 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 230000003211 malignant Effects 0.000 claims description 11
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 6
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 5
- 239000002751 oligonucleotide probe Substances 0.000 claims description 5
- 238000011109 contamination Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000001105 regulatory Effects 0.000 claims description 4
- 206010003816 Autoimmune disease Diseases 0.000 claims description 3
- 102100011540 LGALS3 Human genes 0.000 claims description 3
- 108020004999 Messenger RNA Proteins 0.000 claims description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229920002106 messenger RNA Polymers 0.000 claims description 3
- 229960000060 monoclonal antibodies Drugs 0.000 claims description 3
- 230000003169 placental Effects 0.000 claims description 3
- 241001515965 unidentified phage Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 101710015834 LGALS3 Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 2
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 102100001597 PIAS1 Human genes 0.000 description 145
- 235000018102 proteins Nutrition 0.000 description 100
- 241000699666 Mus <mouse, genus> Species 0.000 description 65
- 235000000346 sugar Nutrition 0.000 description 32
- 230000000694 effects Effects 0.000 description 24
- 210000002966 Serum Anatomy 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000002523 lectin Substances 0.000 description 14
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 13
- 239000008101 lactose Substances 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 230000022131 cell cycle Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 229940088598 Enzyme Drugs 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 101710015954 HVA1 Proteins 0.000 description 7
- 101700065814 LEA2 Proteins 0.000 description 7
- 101700021338 LEC Proteins 0.000 description 7
- 101700077545 LECC Proteins 0.000 description 7
- 101700028499 LECG Proteins 0.000 description 7
- 101700063913 LECT Proteins 0.000 description 7
- 108090001090 Lectins Proteins 0.000 description 7
- 102000004856 Lectins Human genes 0.000 description 7
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 101710034340 Os04g0173800 Proteins 0.000 description 7
- 230000004520 agglutination Effects 0.000 description 7
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 7
- 101700036391 lecA Proteins 0.000 description 7
- 101700001016 mbhA Proteins 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 102000004338 Transferrin Human genes 0.000 description 6
- 108090000901 Transferrin Proteins 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 239000012581 transferrin Substances 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- 101700066277 COS-1 Proteins 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 108010044715 asialofetuin Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229960001322 trypsin Drugs 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 229920001405 Coding region Polymers 0.000 description 4
- 241000272184 Falconiformes Species 0.000 description 4
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 4
- 102000007312 Recombinant Proteins Human genes 0.000 description 4
- 108010033725 Recombinant Proteins Proteins 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003636 conditioned culture media Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 230000035521 G2 Phase Effects 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000036191 S Phase Effects 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001085 cytostatic Effects 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108010029014 succinylconcanavalin A Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940047124 Interferons Drugs 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000000459 effect on growth Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 108091005600 glycosylated proteins Proteins 0.000 description 2
- 102000035362 glycosylated proteins Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001894 non-coding RNA Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000001360 synchronised Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 101700036312 CONA Proteins 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 206010015281 Erythroleukaemia Diseases 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000304160 Sarcophaga carnaria Species 0.000 description 1
- 241000257193 Sarcophaga peregrina Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- -1 adjuvent Substances 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000004135 animal tissue culture Methods 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108091007726 carbohydrate binding proteins Proteins 0.000 description 1
- 102000026868 carbohydrate binding proteins Human genes 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108091011898 galactoside binding proteins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010072285 growth inhibitory proteins Proteins 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002390 hyperplastic Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108091005963 iodinated proteins Proteins 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000503 lectinlike Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Description
CELL GROWTH INHIBITORS
LIVIO MALLUCCI and VALERIE WELLS
The invention relates to proteins known as
-galactoside binding proteins and to their use to
arrest, control or otherwise affect cell growth.
Proteins capable of binding specific sugars on
cell surfaces have been known for many years. The
sugar binding proteins hitherto known are more_
commonly referred to by the generic term "lectin". A
lectin is defined as a carbohydrate binding protein
which has a specificity for particular sugar
residues, is bivalent or polyvalent with respect to
sugar binding and is at least bivalent if monomeric
(Barondes, H, Science 22;, 1259-1264 (1984)).
the multivalency it is a further characterising
Due to
property of lectins that they cause agglutination of
red blood cells i.e. they are haemagglutinins and can
also cause agglutination of other cells because of
their affinity for sugars on the cell surface. Also,
because of their cross—linking property, which
relates to bivalency or polyvalency they can impede
cell proliferation. However their effect is
indiscriminate, physiologically irreversible and they
are highly toxic.
Particularly well-known examples of lectins are
the plant proteins Concanavalin A and
phytohaemagglutinin. More recently, sugar binding
proteins have been identified in many other
organisms, including vertebrates and slime moulds.
Vertebrate proteins in this class have been described
and characterised, for example, in the following
references:—
— Barondes, H., Science 223, 1259-1264 (1984)
- Ohyama, Y., Hirabayashi, J., Oda, Y., Ohno, S.,
Kawasaki, H., Suzuki, K., and Kasai, K. Biochem.
Biophys. Res. Comm. 111, 51-56 (1986)
Southan, C., Aitken, A., Childs, R.A., Abbott,
W.M. and Feizi, T. FEBS Lett. 215, 301-304 (1987)
Hirabayashi, J and Kasai, K. J.Biochem.(Tokyo)
igg, 1-4 (1988)
Clerch, L.B., Whitney, P., Hass, M., Brew, K.,
Miller T., Werner, R and Massaro, 0. Biochemistry
11, 692-699 (1988)
Couraund, P.O., Casentini-Borocz, D.,
Abbott, M.W., and Feizi, T. Biochem J. ggg, 291-294
(1939)
— Wilson, T.J. G., Firth, M.N., Powell, J.T., and
Harrison, F.L., Biochem. J. 261, 847-852 (1989)
- Hirabayashi, J., Kawasaki, H., Suzuki K., and Kasai,
K., J. Biochem. 1 1, 987-995 (1987)
It will be apparant from the above definition
of a lectin that, as 3-galactosides are sugars,
fi—galactoside binding proteins fulfil one of the
criteria of the lectins and it was hitherto
understood that all fl-galactoside binding proteins
were in fact lectins. It is demonstrated herein by
the present inventors that this is in fact not the
case.
Plant lectins have been known to cause
lymphocyte activation. EP-A-0337299 describes also
the use of lectins from a variety of vertebrate
sources in the treatment of diseases involving
defects in the immune system such as myasthenia
gravis and reumatoid arthritis. A beneficial effect
on diabetes and multiple sclerosis is also suggested.
In EP-A-0260497 a "lectin-like" protein
isolated from a cell line of Sarcophaga peregrina
(flesh fly) is described which acts as a
haemagglutinin and which has an inhibitory effect on
the growth of tumours in mice.
The above documents‘ claims are however based
on the lectin characteristics of the proteins used.
The present inventors, in the search for new and
improved cytostatic agents, have now isolated,
purified and characterised a new cytostatic protein
capable of inhibiting or arresting the growth of both
normal and cancer cells, which is produced by mouse
embryo fibroblasts and which does not fulfil_the”*
criteria for a lectin nature. By determination of
its amino acid sequence and comparison of the
sequence of isolated peptides with the known
sequences of other proteins using literature and
database searches it has been established that the
inhibitor is a fl-galactoside binding protein
(GBP). This has been confirmed by cDNA cloning and
expression of the protein in recombinant form.
It has further been discovered by the inventors
that the protein is not a lectin in accordance within
the classical definition because it is monomeric and
because it is monovalent with respect to sugar
binding sites or it has no available sugar binding
site because it is masked by a glycan complex. It is
thus incapable of causing blood cells or other cells
to agglutinate. Furthermore it does not exist in
dimeric form as reported for the lectins but rather
as a native monovalent monomer. Alternatively, it
can form tetramers in which the four 5-galactoside
binding sites are internal and thus not available to
cause cell agglutination, even where no glycan
complex is associated with the molecule. Furthermore
the cytostatic effect is not exerted through the
sugar binding site but is exerted through domains
which bind with high specific affinity to specific
cell surface receptors.
The invention described herein is based on the
aforementioned discoveries and also on the further
discovery that the cytostatic and non-agglutinating
GBP from mouse embryo fibroblasts has an inhibitory
effect on growth of human cancer cells. The
invention is thus directed to embodiments of these
discoveries, i.e. non-agglutinating GBP's having the
properties hereinbefore described, whether from
natural animal sources or produced by recombinant DNA
technology, for‘use as inhibitors and regulators of
cell growth and as therapeutic agents. Although this
new cell growth inhibitory protein has been isolated
from mouse tissue it is to be expected that
equivalent proteins having the same properties can be
isolated from other species.
Thus in accordance with the invention there is
provided a non-agglutinating B~galactoside binding
protein which is monomeric and monovalent or
tetrameric for use as a therapeutic agent. The
protein is suitable for use as an inhibitor of growth
of vertebrate cells, in particular for use as a
therapeutic agent in the treatment of malignant
disease or auto—immune disease. The inventors have
also shown the non—agglutinating B-galactoside binding
protein described herein to have anti-viral
properties. Accordingly, therapeutic use as an anti-
viral agent is also envisaged. The non-agglutinating
B-agglutinating binding protein for use as described
herein is an animal protein but may be prepared
synthetically, for example by recombinant DNA
technology.
It is to be understood that herein the term
fi—ga1actoside binding protein means a material
having the amino acid sequence of the native protein
or any modification thereof which maintains the
domain or domains with capacity to bind the specific
Such
modifications may include proteins which have amino
cell surface receptors of the target cell.
acids added or removed or having changes to amino
acids which do not effect the growth inhibitory
activity thereof.
Further as used herein the term
non-agglutinating describes a protein which in native
form has an affinity for binding sugar but which is
incapable of causing cell agglutination as the direct
Thus cap’?
capable of causing agglutination by some other
result of that sugar binding affinity.
biochemical mechanism are not excluded.
Preferably the GBP for use in the invention is
from a vertebrate source but GBP's from other sources
are not excluded.
Preferably the cells are transformed cells and
more preferably transformed cells of human origin.
It is to be understood that the term ‘transformed
cells‘ includes within its definition, cancer cells,
all forms of malignant cells and all cells from
benign tumours as well as pre-malignant,
pre-transformed, hyperplastic and all irregular and
undesired forms_of cell proliferation. In
particular the recombinant GBP's of human or animal
origin may be used as therapeutic agents in the
treatment of human malignant diseases. Preferably
the GBP for such use will have or include an amino
acid sequence of a GB? of either human or mouse
origin although sequences originating from other
species are not excluded. Both the native mouse and
human GBP consist of 134 amino acids and share 89%
homology. It has been clearly demonstrated by the
present applicants that there is a cross species
effect: i.e, mouse GBP inhibits growth of human
cancer cells. Thus a GB? of either human or mouse
origin, as well as other species, may be used as a
therapeutic agent in humans or other animal species.
It is to be expected that GBP's from other species
will also have an inhibitory effect on the growth of
human cells because a high degree of amino acid
sequence homology has been demonstrated between the
human non-agglutinating 5-galactoside binding
protein and GBP's from other species. Accordingly,
such other GBP's are within the scope of the
invention. '
It is further demonstrated herein with
reference to the recombinant mouse GBP that these~w
proteins have the effect of maintaining cells in GO
and of preventing or reducing traverse through the G2
phase of the cell cycle and hence entry into
mitosis. This particular property of the protein can
be particularly advantageous from the point of view
of therapy against malignant cells in G0 which are
prevented from resuming growth and against
proliferating malignant cells.
Furthermore the non-agglutinating property of
these GBP's makes them suitable as therapeutic agents
because agglutination'of cells in body fluids and in
tissues when a protein is given therapeutically is of
course undesirable.
The GBP's for the use of the invention are
monomeric and monovalent with regard to B-galactoside
binding sites but preferably are monomeric with the
single sugar valency masked, modified or removed alto-
gether. They may also be tetrameric but with no sugar
valency exposed. It will be understood from the
information given herein that the tetrameric form is
still non-agglutinating (as herein defined) and
Both
the monomeric and tetrameric forms may be associated
therefore within the scope of the invention.
with a saccharide or a saccharide complex, preferably
a polysaccharide complex such as a glycan complex,
but non—saccharide complexes are not excluded.
Most preferred saccharide complexes are those
containing sialic acid which protects the complex
associated GBP from clearance from the circulation by
carbohydrate specific receptors on macrophages,
hepatocytes or by other clearance systems.
A saccharide complex can be acquired, as in the
case presented herein by way of example, or it can
orginate within the molecule from a glycosylation
site whether natural or engineered. It is envisaged
that by the technique of site directed mutagenesis*a
glycosylation site can be created in order to allow
masking of the saccharide binding site or that a
complex other than a saccharide complex can be used
or engineered in order to mask the saccharide binding
site. Such a protein where the saccharide binding
site is occluded has a therapeutic advantage for the
reasons already mentioned and because of its
stability and greater growth inhibitory activity. A
GBP in which the fi—galactoside binding site is
masked by a complex is hereinafter described as the
"complexed" form of the protein. This term is used
whether the complex is acquired, as in the case
described herein, or whether it originates within the
molecule from for example a glycosylation site.
It is of course further envisaged that the
fi—galactoside binding protein, in accordance with
the invention may be modified such that the
saccharide binding site, rather than being masked is
removed altogether. Such proteins are still within
the scope of the invention.
Non—agglutinating B-galactoside binding proteins
for therapeutic use in accordance with the invention
can form a pharmaceutical composition which comprises
an effective amount of said protein together with a
carrier or diluent.
Preferably the composition is formulated for
parenteral administration or for other routes and may
include any diluent, adjuvent, preservative or other
component conventionally included in such
compositions and well-known to those skilled in the
art. Where the composition is formulated in unit
dosage form it is preferably such that the patient
receives from 10 ng to 1000 mg per dose, depending on
the particular therapeutic use and the sensitivity of
the target cells:
The GBP may also be used tagged or attachedmto
another protein or molecular carrier.
In accordance with a second aspect of the
invention there is provided a method of producing a
pharmaceutical composition which comprises the non-
agglutinating B-galactoside binding protein as defined
herein which method comprises at least the steps of:-
(a) providing an organism, either unicellular
or multicellular which expresses said
protein,
(b) allowing expression of said protein,
(c) separating and identifying said protein in
impure form from said organism,
(d) subjecting said protein to a purification
procedure to produce a product
substantially free from contamination
derived from the expressing organism, and
(e) formulating said protein into a
pharmaceutical composition with a suitable
carrier or diluent.
The organism which produces the GBP may
comprise animal cells which express the protein
constitutively and can be cultivated to produce the
protein on a commercial scale. A wide range of
animal cell lines may be used to produce GBP in this
manner including those originating from insects,
fish, humans and other mammals. The constitutively
expressed protein can be readily harvested,
identified and purified from tissue culture medium in
which the cells"lines are grown by standard
techniques known to the man skilled in the art.
Particularly preferred for commercial production of
GBP are continous cell lines, especially those which
grow in suspension culture.
In the examples described herein the inventors
have for convenience harvested and purified GBP from
secondary mouse embryo fibroblasts.
Alternatively the organism which produces the
GB? may be one which has been engineered by
recombinant DNA technology to produce the protein.
Such organisms will include all the constitutively
producing cell lines referred to above which have
been engineered to give an improved yield and also a
wide range of organisms, both unicellular and
multicellular which would not normally express the
protein but which have had the DNA coding for GBP
introduced therein. Particularly preferred in this
regard are microorganisms such as bacteria, yeasts
and fungi or plant and animal tissue culture cells
but use of higher organisms such as plants and
animals is also envisaged. The genetic engineering
procedures required to introduce a foreign gene into
a microorganism and obtain expression thereof are
well—known to the skilled man in the art.
In the examples described herein the inventors
have used a CDM8 plasmid as an expression vector, and
the murine recombinant protein is expressed in COS-1
- 10 _
cells.
It is also envisaged that GBP's may be isolated
directly from animal tissues. Thus in accordance
with a third_ aspect of the invention there is
provided a method of producing a pharmaceutical
composition comprising a non—agg1utinating B—GBP as
defined herein comprising at least the steps of:-
(a) treating tissue of animal origin to obtain
a protein extract therefrom,
(b) separating and identifying the
non-agglutinating 5-galactoside binding
protein from said extract,
(c) subjecting said protein to a purification
procedure to produce a product \
substantially free from tissue derived
contamination, and
(d) formulating said protein into a
pharmaceutical composition with a suitable
carrier or diluent.
The protein may be extracted, separated and
purified by any one of a number of well-known
techniques. In particular it is possible and indeed
preferable to make use of the GBP's sugar binding
capacity to effect separation of the protein from
other proteins released from the tissue. It is
preferable ifuthe tissues in question are human
tissues and in this regard human placental tissue is
particularly suitable because it is readily
available. Further, placental tissue from other
large mammals such as for example, cows, pigs etc.
may be used as a source of GBP as they are also
available in plentiful supply.
Alternatively GB? or any part thereof may be
- 10a-
prepared synthetically.
In connection with the production of a
recombinant_GBP the following have been deposited at
the National Collection of Type Cultures, 61
Colindale Avenue, London NW9 SAT on 26th April 1989:
a) E. Coli MC 1061/p3 hosting CDM8 plasmid
containing full CDNA coding sequence of murine GBP.
Accession No. 12237
b) bacteriophage lgt 11 containing full CDNA
coding sequence of human GBP. Accession No. 12236.
c) E. coli Y 1090 as host for b). Accession No. 12235
The availability of the above provides means
for the skilled man as a matter of routine, to make
constructs for the expression of animal GBP's from
other sources by simple substitution of the CDNA
inserts or to express mouse or human GBP's using
other vectors. The above plasmid and phage provide
-11..
models for the construction of other vectors and the
expression of other GBP's which can be optionally
engineered to have the sugar binding site masked,
altered or removed.
Although the GBP's of the invention may be
produced by a wide variety of methods as discussed
above, the preparation and isolation of natural and
of recombinant mouse GBP for use in accordance with
the invention was carried out by the inventors by
first culturing secondary mouse embryo fibroblasts
(MEF) and harvesting the culture medium. The natural
protein was purified therefrom by Sephadex gel
filtration followed by reverse phase HPLC.
Synchronous cultures of mouse embryo fibroblasts were
used as test cells to detect cell growth inhibitory
activity and the degree of inhibition was assessed by
direct counting of cells and by cell cycle analysis
employing cytofluorometry.
The protein was characterised by first
obtaining the amino acid sequence of three peptides
by standard procedures and then searching in the
literature and through a protein database for
proteins containing regions of homology with the
It was thus established that the
newly isolated protein was fi—galactoside binding
sequenced peptides.
protein. This was confirmed by CDNA cloning and use
of the recombinant protein for further
characterization studies.
A phage Agt 10 CDNA library was constructed
using mouse embryo fibroblast mRNA as the nucleic
acid source. The knowledge of the peptide amino acid
sequences allowed oligonucleotide probes to be
synthesised to screen the library. From this
exercise a CDNA of 110bp was obtained which served as
a further probe for a CDM8 plasmid library
constructed from size fractionated cDNAs. By this
_ 12 -
route a clone was identified having a CDNA insert
encoding the amino—terminal methionine and a protein
of 134 amino acids with a translated molecular weight
of 14,735 Daltons.
GBP CDNA was used to transfect COS-1 cells in which
The CDM8 plasmid carrying mouse
expression of recombinant mouse GBP (rGBP) was
achieved. The recombinant protein was purified using
anti-mouse GBP antibodies raised by the inventors
although any one of a number of standard purification
methods could have been used. Mouse GBP was shown to
have potent growth inhibitory activity on normal
mouse cells, mouse transformed and cancer cells and
human cancer cells. Further, mouse GBP has been
shown to have an inhibitory effect on viral
replication and is anticipated to have a regulatory
effect on cells of the immune system.
The detailed procedures set out hereinafter are
by way of example of the route to the animal GBP's,
both natural and recombinant, for use in accordance
with the invention. Reference is made to the
accompanying drawings in which:-
Figure 1A shows a reverse phase HPLC tracing in which
two peaks of cell growth inhibitory activity were
identified corresponding to the complexed (Mr 18,000)
and non-complexed (Mr 15,000) forms for the protein,
Figure 1B shows protein bands from the fractions
corresponding to the peaks as shown by SDS gradient
polyacrylamide gel e1ectrophoresis(PAGE) and Biorad
silver staining,
Figure 1C shows the re—isolation of the protein on a
12% SDS gel from fractions eluted from the preceding
polyacrylamide gel as shown in Figure 1B,
Figure lDa shows protein bands obtained on SDS
gradient polyacrylamide gel electrophoresis under
reducing and non—reducing conditions of recombinant
protein expressed in COS-1 cells.
3..
Figure 1Db shows a protein blot stained with a glycan
stain comparing staining of the 18,000 and 15,000 Mr
GBP's of the invention with the glycosylated protein
transferrin and the non—glycosylated N terminus
fragment of transferrin.
Figure 1E shows protein bands obtained on an SDS
gradient polyacrylamide gel elecrophoresis after
treatment of 18,000 Mr GBP with a competing sugar,
with neuraminidase and with an enzyme which breaks 0
saccharide/protein bonds.
Figure 2A shows the amino acid sequence of three
peptides and the homology of these peptides with
amino acid sequences of fi—galactoside binding
protein from vertebrate sources, lack of homology
being limited to the boxed symbols,
Figure 2Ba shows the amino acid sequence of mouse GBP
with the sugar binding site underlined and the
deduced secondary structure,
Figure 2Bb is a hydropathic profile of the protein
with the saccharide binding region in closed symbols,
Figure 3A shows the nucleotide sequence and deduced
amino acid sequence for mouse GBP,
Figure 3B shows the nucleotide sequence and deduced
amino acid sequence for human GBP,
Figure 4A shows the effect of natural and recombinant
mouse GBP which is monomeric on the growth of mouse
embryo fibroblasts (MEF) and the lack of effect, at
equivalent dose, of the plant lectins Concanavalin A
and succinyl Concanavalin A,
Figure 4B shows mouse embryo fibroblasts after 40
hours growth from seeding,
Figure 4C shows mouse embryo fibroblasts 40 hours
from seeding which have been treated with 400 ng
m1‘1 of monomeric GBP,
Figure 40 shows the effect on growth of replicating
MEF of the monomeric forms of GBP and of the
tetrameric forms of GBP over a period of five days,
Figure 4E shows the DNA distribution as an indicator
of cell growth at different stages of the cell cycle
in serum stimulated MEF following treatment with GBP,
Figure 5A shows the effect on cell growth of adding a
neutralizing antibody to the constitutive endogenous
GBP during the G0 phase of the MEF cell cycle,
Figure 5B shows the effect on cell growth when
antibody is added prior to the G2 phase of the cell
cycle,
Figure 6A shows the effect of murine rGBP on growth
of murine transformed cells lines, 18-8, PV—TT—8,
Weli 3B and L—57 at varying concentrations,
Figure 6B shows the effect of murine rGBP on growth
of human cancer cells, K562, Nalm 6 and KG 1 at
varying concentrations,
Figure 7 shows the conversion of non-complexed GBP
from monomeric to tetrameric form (left panels) and
conversion of complexed GBP from monomeric to
tetrameric form (right panels) after 6, 12 and 24
hours of incubation at 37°C.
Figure 8A shows receptor affinity binding of GBP to
mouse embryo fibroblasts in the absence of 100 mM
competing lactose,
Figure 8B shows receptor affinity binding of GBP to
mouse embryo fibroblasts in the presence of 100 mM
competing lactose,
Figure 8C compares the affinity of the four forms of
GBP, (monomeric and tetrameric), for cell receptors
on MEF, and
Figure 9 shows the effect of murine GBP on
replication of EMC virus in mouse embryo fibroblasts.
Example . Isolation of naturally occurring mouse GBP
a) Cultures of mouse embryo fibroblasts (MEF) were
prepared from mice of the C57 Bl strain.
..l5_
Primary cells were seeded in Eagle's BHK medium
containing 10% tryptose phosphate broth and 10%
foetal calf serum (growth medium) in an atmosphere of
% CO2 in air.
Cells were seeded at a density such that when
all cells capable of dividing had undergone one
division cycle, a confluent monolayer was obtained.
Cell division occurred at approximately 30 hours
after seeding and the cultures were then left for a
further 24 hours. These cells were then assessed for
plating efficiency and sub—cultured to secondary
fibroblasts, using a seed equal to half that expected
at confluence. After cell division had occurred (30
hours) the growth medium was changed to BHK medium
containing 2% foetal calf serum and the culture
maintained in this condition for a further 72 hours.
b) For production of natural GBP secondary MEF were
used. Confluent cultures of secondary fibroblasts
which had been quiescent in 2% serum for 72 hours
were washed three times with phosphate buffered
saline (PBS), once with serum free Eagle's BHK medium
(sm) and incubated at 37°C in sm (10 ml per 107
cells) for 20 hours. The medium was harvested,
centrifuged at 10,000g for one hour at 4°C and
concentrated in the cold 100 times by volume above a
The total
protein concentration of the conditioned medium was
PM10 Amicon ultrafiltration membrane.
measured using the Biorad protein assay with
7—globulin as standard.
C) The conditioned medium (CM) prepared in step (b)
was adjusted to have a protein concentration of 1 mg
m1'1 and applied to Sephadex G 75 columns
equilibrated with PBS at 4°C. Elution with PBS was
carried out in the cold. Fractions were collected in
ml volumes, transferred to dialysis bags and
concentrated to 1 ml by withdrawal of water and salts
-16..
using Ficoll 400. Aliquots of each fraction were
assayed for protein concentration, analysed by
polyacrylamide gel electrophoresis and tested for
growth inhibitory activity. The active fractions
were pooled and active protein purified by
immunoaffinity chromatography using polyclonal or
monoclonal anti-GBP antibodies raised and purified by
the inventors as hereinafter described _
d) The cells for assessment of growth inhibitory
activity were secondary mouse embryo fibroblasts.
Cells were seeded at a concentration of 105 cells
cm’? in BHK medium containing 5% foetal calf
serum. The cultures were equilibrated with 5% CO2
in air and incubated in a water-bath at 37°C. At
chosen times the preparations to be tested for growth
Each of these had
previously been dialysed against serum—free medium
(SFM) and then supplemented with 5% foetal calf
Growth
inhibition was measured by removing cells from the
inhibitory activity were added.
serum. Controls received SFM plus 5% serum.
glass using 0.5 ml 0.02% ethylene diaminetetra-acetic
acid (EDTA) containing 0.1% trypsin plus 0.2% trypan
blue.
of serum.
The trypsin was then neutralised with 0.5 ml
Trypan blue stained and unstained cells
were counted in a Fuchs - Rosenthal Haemocytometer.
In all the experiments the number of stained and
therefore non—viable cells was less than 2%.
Example 2. Purification by reverse phase hiqh
pressure liquid chromotoqraphv (HPLC) and
characterisation of mouse GBP.
a) Reverse phase HPLC of proteins was carried out on
pools obtained by G75 Sephadex fractionation of
serum-free conditioned medium from G0 C57/B1
secondary MEF as in Example 1. 250 pg of protein
was loaded onto a C18 reverse phase HPLC column
.
equilibrated with 0.08% trifluoroacetic acid and a
gradient from a 20% to 60% acetonitrile was run over
45 minutes at 1.5 mls min‘1. Fractions of 0.75 ml
were collected. The resulting HPLC trace is shown in
Two peaks of inhibitory activity were
When the pooled
fractions containing the active peaks of inhibitory
Figure 1A.
identified (indicated by arrows).
activity were run on an SDS gradient polyacrylamide
gel the fractions containing the first peak showed a
band with an apparent Mr of about 18,000 Daltons.
Fractions containing the second peak showed one
component migrating with an apparent Mr of about
,000 Daltons.
gel in Figure 1B.
These bands are clearly shown on the
It was ascertained by sequence
analysis and by the use of monoclonal antibodies that
the proteins isolated from the two peaks of
inhibitory activity were in fact identical and the
difference in molecular weight was attributed to the
presence of sugar determinants on the protein of the
first peak and in particular to a saccharide complex
which binds to the B—galactoside binding site and
effectively masks it.
b) 200 pl of the pooled active fractions eluted
in the second peak from the reverse phase HPLC column
were freeze dried and taken up in 50 pl of sample
buffer and run in a single lane of a 12%
polyacrylamide slab gel containing 0.1% SDS. The
lane was cut into 2 mm slices, each slice eluted into
300 pl of Eagle's BHK medium and shaken overnight
200 pl of each
recovered supernatant was spun for 15 minutes at
,000g at 4°C.
polyacrylamide slab gel to be stained with Biorad
on a rotary shaker at 4°C.
50 pl were run on a 12% SDS
silver stain. This gel is shown in Figure 1C. The
remaining 150 pl of recovered supernatant were
then made to contain 5% foetal bovine serum and 1%
-18..
fatty acid free bovine serum albumin and added to
duplicate cultures of tertiary mouse embryo
fibroblasts in multiwell plates. For assessment of
growth inhibitory activity cells were fixed in
methanol at 40 hours from seeding and stained. The
cell number in 5 random fields was counted using an
eye piece graticule. Figure 1C clearly shows a band
migrating with the expected Mr which coincides with a
sharp peak of cell growth inhibitory activity.
c) Following the purification by virtue of steps (a)
and (b) above, amino acid sequence analysis was used
for characterisation of the protein at the structural
level. Pooled active fractions as shown in Figure 1A
were reduced and alkylated, dialysed against 10 mM
ammonium bicarbonate, lyophilised and resuspended in
10mM ammonium bicarbonate. TPCK treated trypsin was
added (100:1, Protein : trypsin, W/W).
was incubated at 37°C for 12 hours, a further
This mixture
identical aliquot of trypsin added and the incubation
continued for a further 12 hours.
Peptides were then loaded directly onto a C18 reverse
phase HPLC column equilibrated in 0.08%
trifluoroacetic acid.
A gradient from 0 to 60% acetonitrile was run over 75
minutes at 1 ml min‘1 and 0.5 ml fractions were
collected. Sequence determination was carried out on
three peptides so produced using an Applied
Biosystems 470A gas phase sequencer, PTH amino acid
analysis being performed on—line using a 120A
analyser.
Quantitative PTH amino acid recovery was measured
with a Shimadzu CR3A recording integrator. The three
peptide sequences obtained are shown in Figure 2A.
A protein database and literature search was
performed to identify other proteins showing homology
with these three peptide sequences mentioned above.
The searches revealed an absolute amino acid identity
with sequences of rat lung fi—galactoside binding
protein, absolute identity, with the exception of one
amino acid, with sequences of 5-galactoside
binding protein from some human tissues and homology
with available sequences of other human tissues and
tissues from mouse, cow and chicken. This is shown
in Figure 2A where boxed sequences indicate lack of
homology. Thus the peptide sequence analysis and
subsequent search showed clearly that the MEF
inhibitory protein was fi—ga1actoside binding
protein. Confirmation that such was the case was
made by cloning full length GBP CDNA (as described
hereinafter) and comparing the deduced amino acid
sequence of mouse GBP with the GBP's of other species
as specified in Example 3.
d) Once the full amino acid sequence of GBP was
obtained computer analysis was used to identify the
position of any fi-galactoside binding sites.
Figure 2Ba shows the amino acid sequence with the
predicted secondary structure indicated and the
single saccharide binding site underlined.
Figure 2Bb is a hydropathic profile of the
protein in which the amino acids of the saccharide
binding site are in closed symbols. The protein,
both natural and recombinant, is expressed in
monomeric form (see Example 6). The above analysis
clearly demonstrates that the monomeric protein has
This
characteristic distinguishes it from the lectins and
only a single fi—galactoside binding site.
prevents it from causing cell agglutination.
Example 3. Preparation and Isolation of Mouse GBP
cDNA from Mouse Embryo Fibroblast cDNA Libraries
a) The amino acid sequence of part of one of the
peptides shown in Figure 2A (the sequence that is
underlined) was used to deduce a nucleotide sequence
for synthesis of four oligonucleotide probes by
standard methods known to the skilled man.
b) Po1yA+ RNA was isolated from tertiary mouse
embryo fibroblasts. Double stranded CDNA was
synthesised from this mRNA, ligated into phage
Agt 10 DNA and the recombinant phage was packaged
in vitro. The Agt 10 CDNA library was then
screened in a standard manner with a combination of
the four synthetic oligonucleotide probes based on
A llobp
CDNA, enclosing the coding region for the amino acid
the peptide sequence described previously.
sequence of the peptide used to prepare the
oligonucleotide probes, was then isolated and used to
screen a CDM8 plasmid library prepared with size
fractionated cDNA's (400 to 1200 bp) prepared from
mouse fibroblast polyA+ RNA. XhoI CDNA inserts
were isolated and selected by size for sequencing by
the Sanger dideoxynucleotide termination method.
Clone MW2 was found to consist of 495 nucleotides
enclosing an open reading frame of 405 bp with the
ATG starting codon in favourable initiation context.
Clone MW2 cDNA encodes the amino-terminal methionine
and a protein of 134 amino acids with a translated
Flanking the
coding region are a 5' untranslated sequence of l9bp
molecular weight of 14,735 Daltons.
and a 3' untranslated sequence of 71 bp containing a
stop codon in position 406, a consensus adenylation
signal 23bp further downstream and a tail of 19
adenosines. The nucleotide sequence for MEF GBP is
shown in Figure 3A. Comparison with known sequences
of rat, human and chicken beta galactoside binding
proteins, showed that the GBP's described herein,
each consisting of 134 amino acids, showed the
following homologies: mouse/rat 96%, mouse/man 89%,
mouse/chicken 50%. Hence, especially in the case of
mammalian GBP, molecular similarity is very high.
This explains the cross—species activity i.e. effect
of mouse GBP on human cancer cells as quoted in
Example 5.
Example 4. Expression of GBP in COS-l Cells and
Purification of the Recombinant Protein.
a) COS-1 cells which do not naturally express the
protein were transfected with a CDM8 plasmid
containing the aforementioned clone MW2 at a plasmid
cell ratio of 10 pg DNA per 105 cells using
standard methods based on DEAE dextran and DMSO
facilitated DNA uptake. The thus expressed
recombinant GBP was purified by immunoaffinity
chromatography. Although any purification method
known to the skilled man might be used at this stage,
in this particular example an IgG fraction of a
monoclonal antibody (clone B2) raised against the
natural MEF GBP was used as an affinity reagent.
Because COS—1 cells express both the 15,000 Dalton
protein and the glycan—complexed 18,000 Dalton
version, (which are also expressed under natural
conditions - see Figures 1A and 1B), the antibody
purified rGBP was subjected to asialofetuin sepharose
chromatography. The complexed protein was recovered
in the through fraction while the non—complexed
protein was recovered by elution from the column by
competing sugars.
b) For preparation of a monoclonal antibody to the
natural GBP, 8 to 10 week old BALB-C mice were
immunised intraperitoneally with GBP purified by
electro—elution from a polyacrylamide gel. 50 pg
of protein was injected in Freunds' complete adjuvant
followed by two injections of 50 pg of protein
intraperitoneally in Freunds' incomplete adjuvant at
4 weekly intervals. Immune mice were then boosted by
._22..
injecting with 50 pg of GBP intravenously and the
spleens were removed 3 days later. Spleen cells were
fused with NS—1 myeloma cells using polyethylene
glycol to induce fusion and were then distributed in
selective HAT medium containing 20% foetal calf serum
together with spleen cells to form a feeder layer.
Once clones had grown to a suitable size, the
supernatants were tested for the presence of
antibodies to GBP using an ELISA assay. Positive
clones were sub—cloned twice by limiting dilution and
selected clones were frozen in liquid nitrogen. A
clone, B2, was selected for use in the immunoaffinity
purification of MEF GBP.
Example 5. Growth Inhibitory Activity of Natural and
Recombinant GBP.
a) The growth inhibitory effect of GBP on synchronous
mouse embryo fibroblasts (preparation as described
hereinbefore) was assessed as described in Example
. Increasing concentrations of monomeric GBP were
tested, as also were increasing parallel
concentrations of Concanavalin A and succinyl
Concanavalin A for comparison. Figure 4A shows an
equal increase in growth inhibition up to 100% with
increasing concentrations (0 to 400 ng m1'1) of
(I - I), while no
effect on growth is shown by similar concentrations
either natural (0 - 0), or rGBP,
of Concanavalin A (D-D) or succinyl Con A (aw-A)
which, unlike GBP and other physiological growth
factors such as interferons whose effect is cell
stage specific, require much higher doses and cause
non-specific inhibition. Figure 4B shows a monolayer
of control mouse embryo fibroblasts (MEF) and Figure
4C a monolayer of MEF treated with 400 ng ml'1 of
monomeric mouse GBP between 4 and 40 hours from the
time of seeding. Observations of these cells show
that where replication has been impeded, the cells
tend to have larger cytoplasm and nuclear areas, or
in some cases double nuclei, with cell number not
changed from that of the seed.
b) The growth inhibitory effect of monomeric and
tetrameric forms of GBP were compared. The existence
of tetrameric form of the protein, both complexed
with a saccharide and non-complexed was first
demonstrated by labelling the protein with 125I, as
described in Example 6. The complexed and
non—complexed forms were incubated at 37°C over a
period of 24 hours and then subjected to Sephadex
G100 chromatography and estimation of the
radioactivity in the fractions. The results are
shown in Figure 7 (left panels non-complexed, right
panels complexed) and demonstrate that over the
period of 24 hours the monomer can form a tetrameric
molecule. However as can be clearly seen from the
figures the complexed form resists tetrameric
conversion (Figure 7d, right panel). In the case of
tetramers it can be shown that these molecules result
from the formation of disulphide bridges because the
presence of reducing agents prevent their formation.
The cell growth inhibitory activity of both
types of monomers and tetramers was assessed on
replicating mouse embryo fibroblasts (preparation as
hereinbefore described) at a concentration of 200
ngml'1. The results are shown in Figure 4D and
demonstrate that the inhibitory effect of the
tetramer (o - 0; -D-D-1 is weaker than that of the
,000 Mr monomer fl - u and the 18,000 Mr monomer
V -»V which in fact has the most superior growth
inhibitory activity.
symbolo - O .
inhibitory activity of the tetramer is less is that
Controls are represented by the
A likely explanation as to why the
one tetramer can only bind one cell receptor.
-24..
Furthermore the complexed monomer (18,000 Mr) is the
most potent form of the GBP of the invention probably
because it resists conversion to the tetrameric form.
c) MEF GBP was tested for its effect on a variety of
murine and human cancer cell lines and the results
Growth of the cell
lines incubated with GBP was followed for 3 days and
are shown in Figures 6A and 6B.
the growth rate compared to an untreated control. A
growth inhibitory effect is clearly demonstrated at
100 (A - A) and 400 (Q -0) ng ml'1 GBP when
applied to 18.8 cells (a pre B cell line), PV-TT-8
cells (polyoma virus—induced sarcoma cells), Weli 3B
cells (a myelomonocytic leukaemia cell line) and L-57
(spontaneously transformed mouse fibroblasts),
Figure 6B shows a similar inhibitory effect of GBP
when applied to the human cancer cell lines K562
(chronic myelogenous leukaemia), Nalm 6 (acute
lymphoblastic leukaemia) and KG 1
In both Figures 6A and 6B
controls are shown with the symbols (x - x).
In addition to the above GBP was tested on the
following the human cell lines myeloblastic
(erythroleukaemia).
haemopoietic cell line HL-60, lymphoblastic B cell
line—raji, lymphoblastic T Cell line-MOLT, and
lymphoblastic T Cell line — JM at doses ranging from
100 to 250 ngml‘1 and was seen to cause a decrease
of the S and G2 populations and a reduction of growth
by 40 to 60%. Thus the mouse GBP, both natural and
recombinant, has a powerful inhibitory effect on
tumour cells of human origin.
Example 6. Characterisation of Mouse GBP and
elucidation of its mode of action
a) In order to demonstrate that native GBP was in
fact monomeric both the complexed and non-complexed
-25..
forms, which were separated one from the other by
asialofetuin sepharose chromatography, were subjected
to SDS gradient gel electrophoresis under both
reducing and non-reducing conditions. The result
obtained is shown in Figure 1Da in which lanes a', b‘
and c' were run under reducing conditions and lanes
a,b and c under non-reducing conditions. Since
reducing agents would have the effect of separating
polymeric proteins into monomers which could be
detected on the gel, if mouse GBP was anything other
than a monomer the position of the band would change
where reducing agents were present. As can be seen
this was not the case for either the complexed
protein (lanes a and a‘) or the non—complexed protein
(lanes c and c’). Lanes b and b' represent a mixture
of the two.
to be a monomer.
Thus mouse GBP is clearly demonstrated
b) It has already been demonstrated in Example 2(d)
and particularly shown in Figures 2Ba and 2Bb that
each monomer has only a single 3-galactoside
binding site. This permits binding of the
non-complexed monomer to an asialofetuin sepharose
It has further been demonstrated that the
complexed form and the tetrameric forms of the
column.
protein cannot bind to such a column because they do
not have a sugar binding site available.
In the case of the complexed protein, either
monomeric or tetrameric, the saccharide binding site
is masked by a saccharide complex.
In the case of the tetramer from the
non—complexed form the saccharide binding site on
each component monomer is internal and therefore not
available for binding.
It was first demonstrated that the 18,000 Mr
protein was associated with a saccharide complex by
blotting onto nitrocellulose the 18,000 Mr and 15,0
-26..
Mr forms of GBP, the glycosylated protein transferrin
and the non—glycosylated N—terminus fragment of
transferrin as controls and by using an ELlZA Glycan
Detection Kit (Boehringer Mannheim Biochemica) used
to detect proteins containing sugar complexes. The
result is shown in Figure 1Db in which lane (a) is
18,000 Mr GBP, lane (b) is 15,000 Mr GBP, lane (c) is
transferrin and lane (d) is the N—terminus fragment
of transferrin. The concentrations of protein are
from left to right 120 ng, 60 ng and 30 ng
respectively.
The high degree of staining of lanes a and c
Thus the
,000 Mr protein displays such complexes which are
indicates the presence sugar complexes.
clearly absent in the 15,000 Mr protein.
The nature of the binding of the glycan complex
was further investigated to see whether there was
0-glycosylation of the protein or whether the glycan
complex was linked to the protein by some other means.
The recombinant complexed protein was separated
from the non-complexed protein using asialofetuin
sepharose chromatography where the non-complexed
protein was retained, as described before. The
complexed protein was then subjected to SDS
polyacrylamide gel electrophoresis after enzyme
treatments with 0—deglycosy1ating enzyme in the
presence and absence of lactose and/or
neuraminidase. The results are shown in Figure 1B in
which the treatments are as follows:-
,000 GBP control
18,000 GBP + lactose
18,000 GBP + 0—deglycosylating enzyme
-00‘!!!
,000 GBP + 0-deglycosylating enzyme
+ lactose
e 18,000 GBP + 0—deg1ycosylating enzyme
+ neuraminidase + lactose
f 18,000 GBP + 0—deglycosylating enzyme
+ neuraminidase
g 18,000 GBP + neuraminidase + lactose
h 18,000 GBP + neuraminidase
,000 GBP control
The experiment of Figure 1E demonstrates that
the saccharide complex, which contains sialic acid
residues, did not originate from an 0-glycosylation
site of the molecule as it could not be removed by
the deglycosylating enzyme, but that it could be
removed by competition with lactose once the sialic
acid residues of the saccharide complex had been
removed by digestion with neuraminidase.
c) It has been demonstrated by the experiments
described in (b) above that in the complexed GBP the
fi-galactoside binding site is masked by a
saccharide complex. It has also been demonstrated
that the tetrameric forms of the protein do not have
an available sugar binding site because of its
inability to bind to an asialofetuin sepharose
column. Nevertheless these forms of GBP have
demonstrable cell growth inhibitory activity which
indicates that the growth inhibitory effect is not
associated with the sugar binding capacity of the
protein.
In order to demonstrate that the sugar binding
site is not involved in the growth inhibitory effect,
even in the case where it is not masked, affinity
binding of GBP to specific cell surface receptors on
mouse embryo fibroblasts was assayed in the presence
or absence of a competing sugar (Figures 8A and 8B).
Binding assays were carried out also to compare the
affinity of each of the four forms of GBP (monomeric,
complexed and non—complexed and tetrameric, complexed
and non-complexed) for the cell receptors of mouse
embryo fibroblasts (Figure 8C).
Binding assays were undertaken using GBP
labelled with 125:.
radio-iodinated by mixing 1 pg with 500 pCi of
carrier free Na 1251 in 100 pl of 100 mM NaPi,
pH 7 using preloaded iodo—bead iodination reagent.
After stopping the reaction, 300 pl of 100 mM NaPi
with 0.1% BSA was added and the iodinated protein
separated on a Biorad DG10 column equilibrated with
0.1% BSA in 100 mM NaPi.
ranged from 4 x 105 to 8 x 105 cpm pg'1.
The protein was
The specific activity
Samples were checked by polyacrylamide gel
electrophoresis and tested for biological activity
before the binding assays were carried out.
Competition binding assays were carried out at 4°C
on triplicate mouse embryo fibroblast cultures in
Falcon 24 well Multiwell plates. The cells (2 x
per well) which had been pre-refrigerated and
washed three times with cold binding buffer (PBS with
Ca++ and Mg++ plus 0.1% BSA) received 0.625 ng of
125I—1abe1led GBP premixed with increasing
concentrations of un-labelled GBP. Equilibrium
binding was reached at 3 hours and after 4 hours the
cells were washed three times with cold binding
buffer and solubilised in 0.1 mM NaOH, 2% Nag C03
and 1% SDS.
without the presence of 100 mM lactose as a competing
The assay was first carried out with and
sugar. Where competing lactose was added this was
pre-incubated for 20 minutes at room temperature with
the GBP solutions.
are shown in Figures 8A & 8B in which 8A demonstrates
The results of this experiment
the affinity binding of GBP to mouse embryo
fibroblasts in the absence of lactose and Figure 8B
demonstrates binding in the presence of lactose. The
.
inserts are Scatchard plots showing that in either
condition the protein binds to an estimated 5-10 x
104 specific receptors with very high affinity and
that binding must therefore occur through a domain
other than that which binds saccharides. It is clear
from the results of these binding assays that the
lactose is not in any way impeding binding on to
cells and that therefore the sugar binding site
cannot be involved in the growth inhibitory effect of
the molecule as already obvious for the complexed and
the tetrameric forms. In accord with the binding
experiments cells treated with GBP, whether or not in
the presence of a competing sugar, did not proceed
into growth while sugar alone had no effect.
Further receptor binding assays were then
carried out using the four different forms of GBP.
The results are shown in Figure 8C in which (a) is
GBP 15,000 (b) is GBP 18,000, (c) is tetramer of GBP
,000 and (d) is tetramer of GBP 18,000. It is
clear from the results that binding of 125 I labelled
protein was blocked with similar modalities by the
same excess of labelled protein in all instances and
that the estimated number of binding sites per cell
and the relative Kds give similar values (scatchard
insets).
plots, Thus the efficiency of cell receptor
binding is the same for all four forms of the protein.
Example 7. Studies of the mode of action of MEF GBP
on the cell cycle.
a) To investigate the modalities of cell growth
inhibition, cell cycle analysis was performed by
cytofluorimetic quantitation of DNA content of
quiescent and serum stimulated mouse embryo
fibroblasts treated with 400 ng ml'1 of monomeric
GBP. The results of this analysis are shown in
Figure 4E in which (a) represents quiescent G0 cells,
(b) represents cells stimulated by addition of 10%
foetal calf serum, (c) represents serum stimulated
cells pretreated during Go from 4 hours prior to
serum stimulation, (d) represents cells treated from
the beginning of G1 (3h after serum stimulation) and
(e) cells treated from 4 hours prior to G2.
It was found from these cell cycle studies that
when untreated control cells (4Eb) were traversing
G2, cells treated with GBP in G0 remained held in GO
(4Ec). The cells treated in G0 had not divided by
the time the control cells had completed their
cycle. Further experiments (not shown) showed that a
similar effect was achievable with concentrations of
GBP lower than 50 ng ml‘1. Thus GBP can inhibit
cell proliferation by blocking cells in G0.
When GBP was added during G1 (Figure 4Ed)
progress to the S phase of the cell cycle was not
inhibited but instead the transition from late S
phase through G2 was affected. Traverse from late S
phase through G2 was also affected when GBP was added
The cells
did not divide by the time control cells had
prior to the cells entering G2 (Fig 4Ee).
replicated. Again further experiments (not shown)
showed that cell growth was delayed for several hours
with doses as low as 10 ng ml'1. It is envisaged
that in a different experimental system even lower
doses would be effective.
Concanavalin A and succinyl Concanavalin A were
also tested in these cell cycle experiments at the
same dose and shown to have no effect.
b) The regulatory role of the constitutive,
endogenous GBP was further investigated by examining
the effect of a neutralizing monoclonal antibody to
mouse GBP on the endogenous protein. Monoclonal
antibodies were raised to GBP which was purified by
HPLC and eluted from a sliced gel. Eliza positive
clones from Balb/C-NS-1 myeloma hybrids were
subcloned twice and the IgG fraction from clone B2
was purified using rabbit anti—mouse IgG.
The neutralizing antibody was first added to
mouse embryo fibroblasts in the G0 phase. In Figure
5A, (a) represents quiescent (GO) cells, (b)
represents serum stimulated control cells and (c)
represents cells treated from 6 hours prior to serum
stimulation. In a second experiment, the results of
which are shown in Figure 5B, neutralizing antibody
In this
case the cells were (a) quiescent (G0) cells, (b)
was added prior to the entry into G2 phase.
serum stimulated control cells and (c) cells treated
from 6 hours prior to G2. In both experiments the
amount of neutralizing antibody added was 0.5 pg
ml‘1.
From the results shown in Figure 5A it can be
seen that cells treated previous to serum stimulation
(c) traversed S and G2 some 2 hours earlier than
controls (b). This indicates that in mouse cells
constitutive GBP has a role in maintaining cells in
the stationary state. The results in Figure 5B show
that in cells exposed to antibodies previous to entry
into G2, progress through S and G2 was faster (c)
than in the untreated cells (b), indicating a role
also in the control of this period of the cell cycle.
The experiments of Example 7 show that GBP
inhibits cell proliferation with cell stage
specificity as in the case for interferons which
operate in G0 and in G1, and that its effect is
therefore that of a cytokine and not that of a lectin.
Example 8. Studies on effect of GBP or Viral
Replication.
Murine rGBP was tested for its anti-viral
activity against the RNA virus enchephalomyocarditis
virus (EMC). Mouse embryo fibroblasts were infected
_32_.
with EMC virus at 10 plaque forming units per cell
The extent of
viral replication was measured by incorporation of
and GBP added after virus absorption.
H—uridine into the viral RNA after treatment of
the MEF with actinomycin D to halt the host cell RNA
production. The infected cells were treated with
200, 20 and 2 ng ml‘1 GBP and the level of viral
replication compared with controls. The results are
shown in Figure 9 and clearly demonstrate that, even
at a concentration as low as 2 ng ml'1 GBP causes a
significant reduction in the replication of the virus.
Accordingly GBP's as defined herein have
potential use also as anti-viral agents.
CDNA for human GBP
The CDNA for a human non-agglutinating
Example 9.
fl—galactoside binding protein which is monovalent
with respect to sugar binding (human GBP) has also
been cloned by the inventors in bacteriophage xgt
11. The nucleotide sequence and the deduced amino
acid sequence (134 amino acids M.W.l4,744) is shown
in Figure 3B. Given the clearly demonstrated growth
inhibitory effect of the mouse GBP on human malignant
cells, which would not have been expected from prior
knowledge, it is reasonable to assume that the
equivalent human protein will have an even more
powerful growth inhibitory effect on human malignant
cells.
This newly discovered inhibitory activity of
animal fl-galactoside binding proteins means that
they possess enormous potential as therapeutic agents
in malignant disease. Further a regulatory effect is
to be expected on cells of the immune system and thus
a therapeutic use in auto-immune diseases is also
envisaged.
._33..
In addition, it has further been demonstrated
by the inventors that the proteins of this class also
have an inhibitory effect on viral replication, thus
providing another potential therapeutic use.
The isolation and purification of a naturally
occurring non-agglutinating mouse GBP, its production
by recombinant DNA technology and its powerful
inhibitory effect on growth of mouse and human
transformed cells and on viral replication has been
given merely by way of example of the potential use
of these non—agglutinating animal GBP's generally,
and in particular, the potential use of a GBP of
human origin. Given the knowledge that these animal
GBP's can possess this powerful growth inhibitory
effect it is within the ordinary abilities of the
skilled man to produce other GBP's having therapeutic
use by this route.
Claims (27)
1. A non-agglutinating B—ga1actoside binding protein which is monomeric and monovalent or tetrameric for use as a therapeutic agent.
2. A non-agglutinating B-galactoside binding protein as claimed in claim 1 for use as a therapeutic agent in the treatment of malignant disease.
3. A non-agglutinating B-galactoside binding protein as claimed in claim 1 for use as a therapeutic agent in the treatment of auto-immune diseases.
4. A non-agglutinating B-galactoside binding protein as claimed in claim 1 for use as an anti-viral agent.
5. A non-agglutinating B—ga1actoside binding protein as claimed in any one of claims 1 to 4 the B- galactoside binding site of which is masked, modified or removed.
6. A non-agglutinating B-galactoside binding protein as claimed in claim 5 the B-galactoside binding site of which is masked by a saccharide complex.
7. A non-agglutinating B-galactoside binding protein as claimed in claim 5 the B-galactoside binding site of which is masked_by a saccharide complex containing sialic acid.
8. A non-agglutinating B—galactoside binding protein as claimed in any one of the preceding claims 35 which is attached or tagged to another protein or molecular carrier.
9. Use of a non-agglutinating B—galactoside binding protein which is monomeric and monovalent or tetrameric as an inhibitor of growth of vertebrate cells in vitro, or a regulator and controller of vertebrate cell growth and replication in vitro.
10. Use of a non—agglutinating B-galactoside~“ binding protein which is monomeric and monovalent or tetrameric in the manufacture of a medicament for inhibiting the growth of vertebrate cells or for regulating and controlling the growth and replication of vertebrate cells.
11. Use of a non—agglutinating B-galactoside binding protein which is monomeric and monovalent or tetrameric in the manufacture of a medicament for treating malignant disease.
12. Use of a non-agglutinating B-galactoside binding protein which is monomeric and monovalent or tetrameric in the manufacture of a medicament for treating viral infections.
13. A method of producing a pharmaceutical composition which comprises a non-agglutinating B-galactoside binding protein in accordance with any one of claims 1 to 4 which method comprises the steps of:- (a) providing a cell—line, or a microorganism which expresses said protein, (b) allowing expression of said protein, (c) separating and identifying said protein in impure form from said cell—line, or microorganism, (d) subjecting said protein to a purification procedure to produce a product substantially free from contamination derived from the expressing cell—line or microorganism, and (e) formulating said protein into a pharmaceutical composition with a suitable carrier or diluent.
14. A method as claimed in claim 13 wherein said cell- line is a cell line derived from animal tissue.
15. A method as claimed in claim 14 wherein said cell line is a human cell line.
16. A method as claimed in claim 14 or claim 15 wherein said cell line is a continuous cell line.
17. A method as claimed in any one of claims 13 to 16 wherein said cell—line or microorganism is engineered to produce said protein by recombinant DNA technology.
18. A method as claimed in claim 13 wherein said microorganism is a microorganism selected from a bacterium, yeast or fungus which is engineered to produce said protein by recombinant DNA technology.
19. l5, l6, A method as claimed in any one of claims 13, 14, 17 or 18 wherein the cell—line or microorganism expressing said protein is manipulated to contain the cDNA of murine non—agglutinating B—galactoside binding protein originating from the NCTC deposited plasmid with Accession NO. l2237. U: 37
20. A method as claimed in any one of claims 13, 14 I 15, 16, 17 or 18 wherein the cell—line or microorganism expressing said protein is manipulated to contain the CDNA of human non—agglutinating B—galactoside binding protein originating from NCTC deposited phage with Accession No. 12236.
21. A method as claimed in claim 17 or claim 18 wherein said engineered cell—line or microorganism is produced by the steps of:— (a) providing a CDNA library in which the cDNA corresponds to mRNA harvested from cells of animal origin, (b) probing the library with at least one labelled polynucleotide or oligonucleotide probe having a nucleotide sequence which renders it capable of hybridizing to at least a portion of the DNA coding for non—agglutinating fi—galactoside binding protein, (c) excising the DNA coding for the said protein (b), (d) ligating the said DNA into an expression vector, identified in step and (e) introducing said vector into the organism.
22. A method as claimed in claim 21 wherein the coli MC 1061/p3 transformed with a CDM8 plasmid deposited under NCTC 12237. microorganism expressing said protein is E. Accession No.
23. A method as claimed in claim 21 wherein the microorganism expressing said protein is E. coli Y 1090 transfected with bacteriophage lgt 11 deposited under NCTC Accession No. 12236. 35
24. A method as claimed in claim 13 or claim 21 wherein the cell line is mouse embryo fibroblast.
25. A method as claimed in any one of claims 13 to 24 wherein the separation step (c) is carried out by column chromatography and the purification step (d) is carried out by affinity chromatography using polyclonal or monoclonal antibodies to non- agglutinating B—ga1actoside binding protein.
26. A method of producing a pharmaceutical composition comprising a non-agglutinating B- galactoside binding protein according to any one of claims 1 to 4 which method comprises at least the steps of:— (a) treating tissue of animal origin to obtain a protein extract therefrom, (b) separating and identifying the non- agglutinating B-galactoside binding protein from said extract, (c) subjecting said protein to a purification_ procedure to produce a product substantially free from tissue-derived contamination, and (d) formulating said protein into a pharmaceutical composition with a suitable carrier or diluent.
27. A method as claimed in claim 26 wherein said tissue is placental tissue. F. R. KELLY & CO. AGENTS FOR THE APPLICANTS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBUNITEDKINGDOM02/11/19909023907.0 | |||
GB909023907A GB9023907D0 (en) | 1990-11-02 | 1990-11-02 | Cell growth inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
IE83449B1 true IE83449B1 (en) | |
IE913816A1 IE913816A1 (en) | 1992-05-22 |
Family
ID=10684796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE381691A IE913816A1 (en) | 1990-11-02 | 1991-10-31 | Cell growth inhibitors |
Country Status (11)
Country | Link |
---|---|
US (1) | US6127169A (en) |
EP (1) | EP0555286B1 (en) |
JP (1) | JP3497504B2 (en) |
AT (1) | ATE204018T1 (en) |
AU (1) | AU650066B2 (en) |
CA (1) | CA2095335C (en) |
DE (1) | DE69132682T2 (en) |
GB (2) | GB9023907D0 (en) |
IE (1) | IE913816A1 (en) |
IL (1) | IL99940A0 (en) |
WO (1) | WO1992007938A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2134443A1 (en) * | 1992-04-27 | 1993-11-11 | Terry C. Johnson | Inhibitory factor |
US5916871A (en) * | 1992-04-27 | 1999-06-29 | Kansas State University Research Foundation | Inhibitory factor |
AU9301998A (en) * | 1997-09-05 | 1999-03-22 | Board Of Regents Of The University Of Oklahoma, The | Composition and methods using galectin-1 |
US5948628A (en) | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
JP2002322082A (en) * | 2001-04-26 | 2002-11-08 | Purotejiin:Kk | Prophylactic and therapeutic agent for nephritis |
GB2450146A (en) * | 2007-06-14 | 2008-12-17 | Livio Mallucci | ßGBP, compositions comprising ßGBP, and related methods and uses thereof |
US7994113B2 (en) | 2007-06-14 | 2011-08-09 | Livio Mallucci | βGBP, compositions comprising βGBP, and related methods and uses thereof |
AU2008263907B2 (en) * | 2007-06-15 | 2013-05-09 | Basf Se | Low-voc aqueous hybrid binder |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63164895A (en) * | 1986-09-13 | 1988-07-08 | Sanwa Kagaku Kenkyusho Co Ltd | Lectin-like protein originated from cultured cell, its production and antitumor agent composed mainly of said substance |
JP2868777B2 (en) * | 1987-08-20 | 1999-03-10 | チルドレンズ・ホスピタル・コーポレイション | Human mannose binding protein |
AU632474B2 (en) * | 1988-04-14 | 1993-01-07 | Incyte Pharmaceuticals, Inc. | 14-beta-gal mammalian lectins |
-
1990
- 1990-11-02 GB GB909023907A patent/GB9023907D0/en active Pending
-
1991
- 1991-10-30 US US08/050,259 patent/US6127169A/en not_active Expired - Lifetime
- 1991-10-30 JP JP51773391A patent/JP3497504B2/en not_active Expired - Fee Related
- 1991-10-30 AU AU87565/91A patent/AU650066B2/en not_active Ceased
- 1991-10-30 WO PCT/GB1991/001898 patent/WO1992007938A1/en active IP Right Grant
- 1991-10-30 CA CA002095335A patent/CA2095335C/en not_active Expired - Fee Related
- 1991-10-30 DE DE69132682T patent/DE69132682T2/en not_active Expired - Fee Related
- 1991-10-30 GB GB9123036A patent/GB2249312B/en not_active Expired - Fee Related
- 1991-10-30 AT AT91918746T patent/ATE204018T1/en not_active IP Right Cessation
- 1991-10-30 EP EP91918746A patent/EP0555286B1/en not_active Expired - Lifetime
- 1991-10-31 IE IE381691A patent/IE913816A1/en unknown
- 1991-11-01 IL IL99940A patent/IL99940A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7598349B2 (en) | Antibodies to peptide fragments having cell death-inhibitory activity | |
US5451399A (en) | [ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors | |
JP2004194664A (en) | New p-secretin ligand protein | |
CA2098397C (en) | Physiologically active substance designated as epimorphin, genes encoding the same, and antibodies thereto | |
JP2983224B2 (en) | Mammalian 14-β-gal lectins | |
US7018839B2 (en) | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator | |
US5227302A (en) | DNA encoding platelet derived endothelial cell growth factor (PD-ECGF) | |
EP0555286B1 (en) | Cell growth inhibitors | |
IE83449B1 (en) | Cell growth inhibitors | |
PT92613B (en) | METHOD FOR OBTAINING THE ENDOTHELIAL CELL GROWTH FACTOR | |
US5824551A (en) | Method for modulating cell apoptosis | |
US5837239A (en) | Physiologically active substance designated as epimorphin genes encoding the same and antibodies thereto | |
JPH07138296A (en) | Purification and characterization of adhesion receptor of csvtcg specific tumor cell | |
US5756686A (en) | Peptides derived from endothelial cell growth factor | |
JPH06504033A (en) | Lipopolysaccharide-binding opsonin and its use | |
AU711011B2 (en) | Method for modulating cell apoptosis | |
EP0331743B1 (en) | Protein derived from living body | |
EP0712632A1 (en) | Remedy for diseases characterized by abnormal accumulation or activation of leukocyte | |
US6750323B1 (en) | Platelet activation protein | |
JPH08169898A (en) | Peptide and monoclonal antibody |